Cidara Therapeutics, Inc. - Common Stock, par value $0.0001 per share (CDTX) Institutional Ownership

13F Institutional Holders and Ownership History from Q2 2024 to Q4 2025

Type / Class
Equity / Common Stock, par value $0.0001 per share
Symbol
CDTX
Shares outstanding
32,142,857
Price per share
$221.38
All holders as of 31 Dec 2025
Q4 2025
Total 13F shares
33,274,995
Total reported value
$7,347,397,402
% of total 13F portfolios
0.03%
Share change
+686,400
Value change
+$1,521,365,392
Number of holders
243
Price from insider filings
$221.38
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of Cidara Therapeutics, Inc. - Common Stock, par value $0.0001 per share (CDTX) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
VANGUARD GROUP INC 6.4% $443,369,062 2,007,193 The Vanguard Group 31 Dec 2025
BIOTECHNOLOGY VALUE FUND L P 4.4% -16% $113,871,586 -$21,545,460 1,189,165 -16% BVF PARTNERS L P/IL 15 Oct 2025
BlackRock, Inc. 4.6% -15% $111,424,214 +$5,356,584 1,163,607 +5.1% BlackRock, Inc. 30 Sep 2025
Adage Capital Management, L.P. 5% -45% $55,594,000 +$5,559,400 1,100,000 +11% Adage Capital Management, L.P. 30 Jun 2025
Paradigm Biocapital Advisors LP 3.3% -38% $92,041,065 -$16,034,916 961,164 -15% Paradigm BioCapital Advisors LP 30 Sep 2025
Venrock Healthcare Capital Partners III, L.P. 3.2% -67% $32,299,508 -$23,243,750 639,088 -42% Venrock Healthcare Capital Partners III, L.P. 30 Jun 2025
Commodore Capital LP 2% -58% $56,019,600 -$56,498,400 585,000 -50% Commodore Capital LP 30 Sep 2025
Point72 Asset Management, L.P. 1.4% -80% $99,621,000 -$249,731,915 450,000 -71% Point72 Asset Management, L.P. 31 Dec 2025

As of 31 Dec 2025, 243 institutional investors reported holding 33,274,995 shares of Cidara Therapeutics, Inc. - Common Stock, par value $0.0001 per share (CDTX). This represents 104% of the company’s total 32,142,857 outstanding shares.

Top 25 Institutional Shareholders

The largest institutional shareholders of Cidara Therapeutics, Inc. - Common Stock, par value $0.0001 per share (CDTX) together control 68% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.

Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
RA CAPITAL MANAGEMENT, L.P. 10% 3,365,523 0% 7.6% $743,410,375
VANGUARD GROUP INC 6.2% 2,007,193 +63% 0.01% $443,368,862
BlackRock, Inc. 5.2% 1,680,662 +44% 0.01% $371,241,429
HBK INVESTMENTS L P 3.9% 1,260,000 3% $278,321,400
FIL Ltd 3.9% 1,257,574 0.21% $277,785,521
UBS Group AG 3.3% 1,074,924 +127% 0.05% $237,439,963
Darwin Global Management, Ltd. 3.1% 997,196 0% 4.5% $220,180,877
Vivo Capital, LLC 3% 956,670 -27% 14% $211,318,836
STATE STREET CORP 2.8% 884,374 +14% 0.01% $195,349,373
Jefferies Financial Group Inc. 2.4% 766,520 +110% 1.4% $169,316,603
Paradigm Biocapital Advisors LP 2.4% 759,565 -21% 4.5% $167,780,313
Balyasny Asset Management L.P. 2.1% 672,890 +241% 0.28% $148,634,672
Glazer Capital, LLC 2% 650,191 3.8% $143,621,000
Pentwater Capital Management LP 1.8% 565,000 0.9% $124,802,850
MORGAN STANLEY 1.7% 542,722 +44% 0.01% $119,881,979
Beryl Capital Management LLC 1.6% 522,138 12% $115,335,063
GEODE CAPITAL MANAGEMENT, LLC 1.6% 520,591 +29% 0.01% $115,018,309
MILLENNIUM MANAGEMENT LLC 1.6% 509,647 +171% 0.08% $112,575,926
SUMMIT PARTNERS PUBLIC ASSET MANAGEMENT, LLC 1.5% 477,527 +267% 3% $105,480,939
MAVERICK CAPITAL LTD 1.4% 455,978 +9.2% 1.1% $100,720,980
FARALLON CAPITAL MANAGEMENT LLC 1.2% 382,800 -25% 0.49% $84,556,692
GOLDMAN SACHS GROUP INC 1.2% 377,718 +40% 0.01% $83,434,129
Qube Research & Technologies Ltd 1.1% 358,432 +899% 0.11% $79,174,044
CITIGROUP INC 1.1% 348,421 +17795% 0.05% $76,962,715
OCONNOR, A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS (LLC) 0.98% 315,474 8.2% $69,685,052

Institutional Holders of Cidara Therapeutics, Inc. - Common Stock, par value $0.0001 per share (CDTX) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2025 Q4 33,274,995 $7,347,397,402 +$1,521,365,392 $220.89 243
2025 Q3 32,486,735 $3,110,319,924 +$679,666,083 $95.76 167
2025 Q2 25,911,048 $1,262,611,204 +$803,273,260 $48.71 106
2025 Q1 9,559,359 $205,909,478 +$57,592,846 $21.54 45
2024 Q4 6,873,669 $183,637,032 +$100,865,295 $26.88 40
2024 Q3 3,308,428 $35,565,026 +$20,361,776 $10.75 27
2024 Q2 1,412,361 $16,863,937 +$16,863,734 $11.94 25